Hengrui Pharmaceutical announced that Fujian Shengdi Pharmaceutical, a subsidiary of the company, received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for HRS9531 injections and agreed to conduct phase III clinical trials in adult patients with obesity complicated with knee osteoarthritis. This drug is a novel targeted GIPR and GLP-1R dual agonist. It has independent global intellectual property rights, and no similar drugs have been approved for marketing worldwide. Up to now, HRS9531 related projects have invested about 701 million yuan in R&D.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.